Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?

Company Overview - Apellis Pharmaceuticals, Inc. (APLS) shares increased by 5.8% to $23.07 in the last trading session, following a significant trading volume, contrasting with a 13.6% decline over the past four weeks [1] Product Performance - The rise in stock price is linked to growing investor optimism regarding Empaveli (pegcetacoplan), which is approved for treating paroxysmal nocturnal hemoglobinuria in the U.S. The drug generated approximately $35 million in preliminary U.S. net product revenues for Q4 2025, reflecting a 50% year-over-year increase [2] Financial Expectations - The company is projected to report a quarterly loss of $0.41 per share, marking a 41.4% decrease year-over-year. Expected revenues are $194.37 million, down 8.6% from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has been revised 0.8% higher over the last 30 days, indicating a potential for price appreciation [4] Industry Context - Apellis Pharmaceuticals is categorized under the Zacks Medical - Biomedical and Genetics industry. Another company in the same sector, Lexicon Pharmaceuticals (LXRX), saw a 12.3% decline in its stock price, closing at $1.5, despite a 48.7% return over the past month [5] - Lexicon's consensus EPS estimate for its upcoming report remains unchanged at -$0.07, representing a 22.2% increase compared to the previous year [6]